Clinical trials: Neoadjuvant Treatment
Rectal Cancer
Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study
This open-label, multicenter, randomized controlled trial involved 196 patients with pathologically confirmed, previously untreated, resectable MSI-L or MSS/pMMR ultra-low rectal adenocarcinoma.
- Trial name
- NCT07132463
- Testing
- Long-course chemoradiotherapy, Tislelizumab combined with the CAPOX regimen, CAPOX regimen
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Fudan University
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
This phase II trial studies how well enteric-coated (EC) aspirin and rintatolimod with or without interferon-alpha 2b work in treating patients with prostate cancer before surgery.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8
- Trial name
- NCT03899987
- Testing
- EC Aspirin, Radical Prostatectomy, Recombinant Interferon Alfa-2b
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Roswell Park Cancer Institute
Gastric Cancers
R-GASTIM- Study of Gastric Cancer Operable
Clinicobiological cohort of gastric cancers operated in our institution.
- Trial name
- R-GASTIM (NCT07787052)
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Centre Leon Berard
Lung Cancer
Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
The purpose of this study is to test a new approach to the use of standard drugs before surgery in patients with lung cancer. This study will find out what effects, good and/or bad, that this approach has on the cancer.
- Trial name
- NCT01443078
- Testing
- pemetrexed, cisplatin, Carboplatin
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Triple-negative Breast Cancer
A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer
This is a global Phase III, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy and safety of neoadjuvant treatment with atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1] antibody) and…
- Trial name
- IMpassion031 (NCT03197935)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Nab-paclitaxel, Doxorubicin
- Where
- 68 sites in United States, Australia and 11 more
- Volunteers
- 333 people
- Sponsor
- Hoffmann-La Roche
Locally Advanced Gastric Carcinoma
Research on Intelligent Screening and Decision-making for Neoadjuvant Therapy in Locally Advanced Gastric Cancer Based on Multi-omics Integration
In this study, investigators utilize a radiopathomics integrated Artificial Intelligence (AI) supportive system to predict tumor response to neoadjuvant chemoradiotherapy (nCRT) before its administration for patients with locally…
- Trial name
- NCT06396143
- Where
- 4 sites in China
- Volunteers
- 120 people
- Sponsor
- Zhejiang University
Rectal Cancer
FOLFOXIRI With or Without Intensification for Rectal Cancer
Pathologic complete response rate
- Trial name
- NCT03997435
- Testing
- Control arm, Experimental arm
- Where
- 3 sites in Hong Kong
- Volunteers
- 72 people
- Sponsor
- CCTU
Triple-negative Breast Cancer
Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC
We plan to explore the efficacy and safety of albumin-bound paclitaxel+carboplatin+Camrelizumab in neoadjuvant therapy for early TNBC patients, optimize the administration method and drug combination therapy.
- Trial name
- NCT06817525
- Testing
- 6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1), 6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1)
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Henan Cancer Hospital
Surgical Resection, Stereotactic Body Radiotherapy
Post SBRT Pulmonary Metastasectomy (PSPM) Trial
The goal of this study is to determine the effectiveness of SBRT on reducing tumor viability at a pathologic level and also to evaluate the effects of combined modality treatment on low volume pulmonary metastases, in hopes of…
- Conditions
- Surgical Resection, Stereotactic Body Radiotherapy, Lung Cancer, Pulmonary Metastasectomy
- Trial name
- PSPM (NCT04160143)
- Testing
- Surgical resection and stereotactic body radiation therapy (SBRT)
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- McMaster University
Breast Cancer
Percutaneous Biopsy After Neoadjuvant Chemotherapy.
Neoadjuvant chemotherapy is widely used in the treatment of locally advanced breast cancer or in early stages of triple-negative or HER2 overexpressing tumors.
- Trial name
- VAC-Biopsy (NCT07644455)
- Testing
- Pre-Neoadjuvant Chemotherapy Clipping, Vacuum-Assisted Biopsy (VAB)
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Rectal Cancer
MRI Features in Neoadjuvant Treatment Decisions for Patients With Rectal Cancer
This study investigates whether risk criteria based on MRI features could identify a cohort of patients with a good prognosis among those recommended for preoperative treatment by NCCN guidelines to avoid preoperative treatment…
- Trial name
- NCT05609149
- Testing
- total mesorectal excision
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Sun Yat-sen University
Pancreatic Carcinoma
Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
This is a prospective, randomized phase II trial. The aim of this study is to assess the efficacy of two therapeutics strategies.
- Trial name
- NCT02676349
- Testing
- mFolfirinox, Chemoradiotherapy, surgery
- Where
- 26 sites in France
- Volunteers
- 130 people
- Sponsor
- Institut de Cancérologie de Lorraine
Breast Cancer
Exercise Intervention Study for Early-Stage Breast Cancer Patients Receiving Neoadjuvant Therapy.
To determine the effects of endurance exercise training on cardiopulmonary fitness in breast cancer patients undergoing neoadjuvant chemotherapy.
- Trial name
- NCT00405678
- Testing
- Exercise Training, Chemo only
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Duke University
Ovarian Cancer, Fallopian Tube Cancer
Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients
This prospective nonrandomized multicenter phase II study, will evaluate the possibility of performing a laparoscopic interval debulking after a minimum of 3 cycles of chemotherapy in highly chemo-sensitive patients with advanced…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cavity Cancer
- Trial name
- CILOVE (NCT01905163)
- Testing
- Tumor Debulking Surgery by laparoscopy
- Where
- 10 sites in France
- Volunteers
- 47 people
- Sponsor
- Centre Jean Perrin
Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence
The purpose of this study is to evaluate the impact of iparomlimab and tuvonralimab as preoperative neoadjuvant therapy on recurrence-free survival (RFS), along with its potential improvement in overall survival (OS), in patients…
- Trial name
- CCGLC-017 (NCT06954116)
- Testing
- Iparomlimab and Tuvonralimab (QL1706), Partial hepatectomy
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Tongji Hospital
Locally Advanced Rectal Cancer (LARC)
Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
This study explores the key clinical issues in the field of neoadjuvant therapy for locally advanced rectal cancer. There are three core problems with the currently recommended total neoadjuvant therapy (TNT) in the guidelines…
- Trial name
- STELLARIII (NCT07040098)
- Testing
- Sintilimab, Short-course radiotherapy, Long-course concurrent chemoradiotherapy
- Where
- 2 sites in China
- Volunteers
- 228 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Stage II-III Non-small Cell Lung Cancer
Real World Stage II-III NSCLC Patients Receiving Neoadjuvant Chemo-immunotherapy and no Surgical Resection
Neoadjuvant chemo-immunotherapy, with or without adjuvant immunotherapy, is currently the standard of care for resectable stage II-III NSCLC.
- Trial name
- NoSurgery (NCT07131163)
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Sheba Medical Center
Rectal Cancer
Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
The concurrent neoadjuvant chemoradiation therapy is standard care for local advanced rectal cancer (LARC), however, this regimen may induce sorts of adverse events, and part of them even more severer.
- Trial name
- NCT02942563
- Testing
- FOLFOXIRI
- Where
- China
- Volunteers
- 100 people
- Sponsor
- RenJi Hospital
HER2-positive Breast Cancer
Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer
This study is a response-adapted, multicenter, interventional trial enrolling patients with HER2-positive early or locally advanced breast cancer.
- Trial name
- NCT07647263
- Testing
- THP Regimen (Taxane + Trastuzumab + Pertuzumab), Trastuzumab Rezetecan (SHR-A1811)
- Where
- China
- Volunteers
- 124 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Renal Cell Carcinoma (RCC)
Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy
Evaluation of long-term renal function improvement, surgical safety, as well as efficacy and safety of preoperative anlotinib hydrochloride capsules combined with benmelstobart injection versus surgery in patients with localized…
- Trial name
- ALTER-UC-011 (NCT07627464)
- Testing
- Anlotinib hydrochloride + Benmelstobart + Partial nephrectomy, Partial nephrectomy
- Where
- 14 sites in China
- Volunteers
- 144 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.